In a report released today, Gil Blum from Needham maintained a Buy rating on AbSci, with a price target of $7.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Gil Blum has given his Buy rating due to a combination of factors related to AbSci’s development of ABS-201 for androgenetic alopecia (AGA). The recent investor event highlighted the promising preclinical results of ABS-201, which suggest a unique mechanism of action that could offer long-term benefits with a shorter treatment duration compared to existing therapies like minoxidil.
Furthermore, the upcoming HEADLINE clinical study is expected to provide proof of concept by the second half of 2026, with initial safety results anticipated in the first half of the same year. Market research indicates a strong interest in ABS-201’s target product profile among both men and women, with a significant percentage willing to consider it as a frontline treatment despite its injectable nature. These factors, combined with the potential for market dominance and addressing unmet needs, support the Buy rating and the $7 price target.
In another report released on December 4, JonesTrading also maintained a Buy rating on the stock with a $9.00 price target.